Diaceutics

DXRXHealthcare
140.00GBX
0.72%
Market Cap
118.33M
Volume
101.75k
89% of avg
P/E Ratio
0.70
EPS (TTM)
1.99
Beta
0.82
Day Range
139.00p - 142.00p
52 Week Range
106.00p140.00p151.00p
140.00p

Upcoming Events

18 June 2025
Annual General Meeting
30 September 2026
Initial contract timeframe ends
High Impact Event
30 September 2028
Potential contract extension ends
High Impact Event
DXRX
NEUTRAL

Diaceutics PLC Announces Notice of AGM and Posting of Annual Report

The healthcare technology company announces the details of its upcoming annual general meeting and the availability of its annual report.

DXRX
NEUTRAL

Diaceutics Director Sells Shares

The chair of Diaceutics PLC's spouse has sold a portion of their shareholding in the company.

DXRX
GOOD

Diaceutics Reports Strong Revenue Growth of 39% in FY 2024 Results

The diagnostic commercialisation company reported strong revenue growth and improved margins, with expectations to return to profitability in 2025, despite ongoing economic uncertainties.

DXRX
NEUTRAL

Diaceutics Announces PDMR Shareholding and Share Incentive Plan

The healthcare technology company announces changes to PDMR shareholdings and the implementation of a share incentive plan for employees.

DXRX
NEUTRAL

Diaceutics Announces Upcoming Results Presentation

The healthcare technology company announces plans to release its annual results and hold investor presentations.

DXRX
NEUTRAL

Diaceutics PLC Announces PDMR Shareholding and Share Incentive Plan

The healthcare technology company announces changes to its PDMR shareholdings and share incentive plan.

DXRX
VERY GOOD

Diaceutics Secures Lucrative PMx Contract Extension with Partner Therapeutics

The diagnostic commercialization company secures a lucrative contract extension with a major pharmaceutical partner, potentially worth up to £18.5 million in recurring service revenues over the next several years.

DXRX
NEUTRAL

Diaceutics PLC Announces Change in Shareholding

The diagnostic company has announced a change in its shareholder base, with Danske Bank A/S increasing its stake to 3.99% of the voting rights.

DXRX
NEUTRAL

Diaceutics Announces PDMR Share Purchases Under Incentive Plan

The diagnostic commercialisation company announces PDMR share purchases under its employee incentive plan.

DXRX
NEUTRAL

Diaceutics PLC Announces Director Share Purchase

The healthcare technology company announces a non-executive director has purchased a small number of shares, a routine regulatory disclosure.